OrbiMed — 2019 Investments
7 investments dated 2019 · listed companies and verified rows first · show all
BiotechLa Jolla, US
Eric W. Roberts(Executive Officer, Director)Kenneth A. Stauderman(Executive Officer)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Sudarshan Hebbar(Executive Officer)Michael J. Dunn(Executive Officer)
Board seatChau Khuong· per SEC Form D · $80M raise · filed Aug 2019
Co-investorsSanderling VenturesClarus
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsBay City CapitalNew Enterprise Associates (NEA)RA CapitalArix Bioscience
BiotechAustin, US
Matthew Winkler(Director)Sinil Kim(Executive Officer)Paul Lammers(Executive Officer, Director)Jon Irvin(Executive Officer)Casi DeYoung(Executive Officer)
BoardMichael Powell(Director)
Board seatChau Khuong· per SEC Form D · $80M raise · filed Jun 2019
Co-investorsPfizer Venture Investments
AVITA Medical develops therapeutic acute wound care technologies, including the FDA-approved RECELL System that uses a patient's own skin to create a Spray-On Skin cell suspension for treating thermal burn wounds and full-thickness skin defects.
BiotechHealthtechMedical DevicesMelbourne, US
Dale A Sander(Executive Officer)
Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy.
BiotechMedical DevicesSan Francisco, US
BoardChristy Shaffer(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)in
Board seatChau Khuong· per SEC Form D
Co-investorsAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLAVLilly Asia VenturesHatteras
Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders.
BiotechHealthtechMental HealthMilwaukee, US
Daniel Lawton(Executive Officer, Director)Tom Beck(Executive Officer, Director)Chad Beyer(Executive Officer)David Baker, PhD(Director)Ed Barthell, MD(Director)Chad E Beyer, PhD(Executive Officer, Director)
Board seatKlaus Veitinger· per SEC Form D · $6M raise · filed Dec 2019
Co-investorsAisling CapitalF-Prime Capital
HealthtechStamford, US
Daniel S. Lynch(Executive Officer, Director)Saqib Islam(Executive Officer, Director)Michael Greco(Executive Officer)
BoardDeval Patrick(Director)Carl L Gordon(Director)in
Board seatStephen SquintoCarl Gordon· per SEC Form D · $125M raise · filed Apr 2019
Co-investorsBain Capital Life SciencesPfizer Venture Investments
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.